Participated · Seed · Aug 2026

Cirrus Therapeutics is focused on ocular immunology and is based in Cambridge, Massachusetts. Its lead program is a preclinical adeno-associated virus (AAV) ocular gene therapy designed to restore IRAK-M, an immune regulator expressed in retinal cells. The company is targeting dry age-related macular degeneration with the goal of reversing disease and preventing progression to geographic atrophy. Cirrus has raised a seed round now totaling $14.7 million, initially announced at $11 million. Investors in the round include ClavystBio (lead), Polaris Partners, SEEDS (SG Growth Capital) and the Intellectual Property Company of Cedars-Sinai. The company is using the seed-stage capital to advance its preclinical program toward further development.

Participated · Series A · Jun 2026

BeeX develops autonomous underwater drones designed to perform recurrent, regulation-compliant inspections that are cheaper than conventional methods. Its drones have been deployed across Asia-Pacific and Europe to serve offshore wind, oil and gas, subsea cable operators and coastal infrastructure managers. The company also pursues defence applications, including a partnership with Singapore’s Ministry of Defence for national security uses. BeeX is headquartered in Singapore and focuses on expanding operational reach and technological capabilities to meet commercial and defence demand. The recent US$7.7 million Series A will fund fleet expansion and further capability development.

Participated · Seed · Jun 2026

ChemT Biotechnology builds an AI-driven Virtual Cell platform called CelMo, trained on billions to trillions of proprietary sequencing reads and validated in the lab to simulate how cells respond to manufacturing conditions, genetic changes, and stresses. Using CelMo, ChemT identifies target cell pathways, designs small molecules to modulate cell behavior, and supports cell engineering to improve manufacturing performance. The company reports CelMo has delivered a 50% increase in antibody output and a 40% reduction in production timelines in CHO cells. Its flagship small-molecule product Chemplify for T-cell manufacturing has demonstrated 50% faster development, 3× scalability, 60% lower costs, and 10× higher cell expansion yield. ChemT says it has established commercial partnerships with more than 40 pharmaceutical, biotech, and CDMO customers globally. The company plans to expand CelMo beyond CHO and T cells into stem cells, NK cells, and HEK cells while advancing products toward GMP and regulatory readiness.

Participated · Series A · Jun 2026

Pints AI builds Autothought, a platform that plugs into core systems of banks and insurers to automate underwriting, claims, and onboarding while producing a full audit trail for every AI-assisted decision. The platform flags uncertain outputs for human review and is designed to meet requirements of regulators such as the Monetary Authority of Singapore, the Reserve Bank of India, and the Hong Kong Monetary Authority. Pints AI is also developing Autothought Studio, a toolkit intended to let institutions’ engineering teams build and manage AI applications in-house. The company plans to use its $5.6 million pre-Series A raise to expand its engineering team and to build governance and audit capabilities for new regulatory environments. It is pursuing geographic expansion across Asia Pacific and the Middle East. The article did not disclose revenues, user counts, or prior funding details.

Participated · Seed · May 2026

Protuoso Biosciences develops multifunctional MUXBODIES™, fully recombinant fusion proteins designed to integrate antibodies, cytokines, peptides and other signaling modules into single therapeutics that can exert multi-modal functions. Its platform combines computational protein design, massively parallel synthetic biology, and AI-enabled modular protein engineering to optimize multi-domain fusion proteins. The company is building a hub-and-spoke operating model: a central engineering hub that generates diverse assets and spokes that advance programs in parallel and enable early business development. Protuoso has active programs in cardiometabolic diseases, solid tumors (including armored immune cell engagers) and is expanding into autoimmune indications. The company is headquartered in San Carlos, Calif., and positions its model to drive capital efficiency and create multiple value inflection points across the pipeline.